Last reviewed · How we verify
Pf-06700841 (pf-06700841)
At a glance
| Generic name | pf-06700841 |
|---|---|
| Sponsor | Pfizer |
| Drug class | Unknown |
| Target | Unknown |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Multiple Sclerosis
Common side effects
- Nasopharyngitis
- Upper respiratory tract infection
- Headache
- Urinary tract infection
- COVID-19
- Nausea
- Fatigue
- Diarrhoea
- Acne
- Pruritus
- Blood creatine phosphokinase increased
- Bronchitis
Drug interactions
- Warfarin
- P-glycoprotein inhibitors
- P-glycoprotein inducers
- Strong CYP3A4 inhibitors
- Strong CYP3A4 inducers
- CYP2C19 inhibitors
- CYP2C19 inducers
- CYP2D6 inhibitors
- CYP2D6 inducers
- CYP3A4 substrates
- CYP2C19 substrates
- CYP2D6 substrates
Key clinical trials
- A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis (PHASE3)
- A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis (PHASE2)
- Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease (PHASE2)
- A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) (PHASE2)
- Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia (PHASE2)
- Renal Impairment Study of PF-06700841 (PHASE1)
- A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa (PHASE2)
- Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |